EHA 2019 Multiple Myeloma – congress guide

13th–16th June 2019 – Amsterdam RAI, Amsterdam, The Netherlands

Biomarkers & technological advances
Treatment advances
Patient factors
Management advances
Tumour biology

Thursday 13th June (Pre-conference Satellite Symposia)

08:00–09:30 - Hall 5
HEADS - The value of collaborative research in hematology: bringing industry and scientific groups closer towards a common goal

Chair: M Boccadoro

10:15–11:45 - Auditorium
CELGENE – Discovery of the therapeutic synergies leveraging the immune system against MM

Chair: J San Miguel

12:30–14:00 - Elicium 2
AMGEN – Rebooting the MM treatment programme

Chair: J San Miguel

12:30–14:00 - Hall 5
JANSSEN – MM at the cutting-edge: What are the challenges we face today in our clinical practice?

Chair: T Facon

14:45–16:15 - Forum Hall
SANOFI GENZYME – Management of RRMM with novel monocloncal antibody-based regimens: an interactive conversation with the experts

Chair: P Richardson

14:45–16:15 - Hall 3A
MEDSCAPE ONCOLOGY – Real-world treatment of RRMM: Clinical trials vs clinical practice

Chair: G Jackson

17:00–18:45 - Auditorium
MEDSCAPE ONCOLOGY – Building a better foundation: targeting apoptosis to enhance outcomes in RRMM

Chair: S Kumar

19:15–20:45 - Amtrium
GSK – The evolving immunotherapy landscape in RRMM

Chair: S Lonial

19:15–20:45 - Hall 3B
ONCOPEPTIDES – Challenging the treatment paradigm in MM

Chair: X Leleu

Friday 14th June

8:30–9:30 - Hall G106
Aging and hematology: Immunosenescence and immune recovery in older patients

Chair: D Bron

8:30–9:30 - Hall G104
Clonal heterogeneity

Chair: H Avet Loiseau

9:45–10:45 - Hall E106
Resistance mechanisms to novel anti-MM agents

Chair: N Weinhold

11:30–12:30 - Emerald
Optimal sequencing in relapsed/refractory myeloma

Chair: F Gay

11:30–12:45 - Elicium 1
New biological and translational insights into MM

Chairs: H Avet-Loiseau & N van de Donk

13:00–14:15 - Hall 5
Opening Ceremony and Award Lectures

Chair: P Sonneveld

14:30–15:30 - Forum Hall
EHA-JSH Joint Symposium: Cell based therapeutic on the move

Chairs: J Gribben & K Akashi

14:30–15:30 - Hall 5
MGUS with clinical significance

Chair: N van de Donk

15:45–17:15 - Hall 5
Presidential Symposium

Chairs: P Sonneveld & MV Mateos

17:30–18:30 - Elicium 1
EHA Topics-in-Focus: CAR T

Chair: H Einsele

17:30–19:00 - Poster area
Poster session: Myeloma and other monoclonal gammopathies – Biology & Translational Research

Saturday 15th June

08:00–09:00 - Hall 3A
Multiple myeloma: Novel outcome endpoints in trials and in daily practice

Chair: M Delforge

9:05–10:10 - Elicium 1
EHA-ISLH Laboratory Diagnosis Workshop – Part 2: MRD diagnostics: Added value of monitoring circulating tumour cells in blood

Chairs: A Orfao & M Kneba

9:45–10:45 - Hall G104
Immune therapies for hematologic disorders: Novel T cell redirecting strategies

Chair: H Einsele

9:45–11:15 - Auditorium
Multiple myeloma

Chair: S Zweegman

11:30–12:45 - Auditorium
Immunotherapy in relapsed/refractory multiple myeloma

Chairs: A Larocca & E Ocio

13:00–14:30 - Hall 5
Plenary Session 1 and Awards

Chairs: P Sonneveld & MV Mateos

14:45–15:45 - Elicium 2
New agents, new toxicities

Chair: M Federico

14:45–15:45 - Hall E102
EHA-EANM Joint Symposium: FDG PET/CT in Multiple Myeloma: a useful tool?

Chair: TBA

17:30–19:00 - Amtrium
CELGENE – Integrating CAR-T cell therapies into the management of haematological malignancies

Chair: U Vitolo

17:30–19:00 - Hall 3A
OCTAPHARMA – Advancing the management of secondary immunodeficiencies in haematological malignancies

Chairs: O A Cornely & I-K Na

17:30–19:00 - Poster area
Poster session: Myeloma and other monoclonal gammopathies – clinical

Sunday 16th June

8:00–9:15 - Auditorium
Novel strategies in multiple myeloma

Chairs: S Zweegman & F Gay

9:30–10:30 - Hall E103
Quality of life and symptoms: Present and future of patient reported outcome measures in hematology

Chair: E Laane

9:30–11:00 - Elicium 2
Multiple myeloma (repeat session)

Chair: S Zweegman

11:15–12:45 - Elicium 1
Stem cell transplantation

Chair: NPM Schaap

11:15–12:45 - Hall 5
Late-Breaking Oral Session

Chairs: MV Mateos & K Porkka

13:00–14:30 - Hall 5
Plenary Session 2: New treatment strategies in multiple myeloma

Chairs: P Sonneveld & J Gribben

You are now leaving the Myeloma Hub

This link opens another website that is not under the review or control of Takeda UK Ltd and, as such, the company does not endorse the content, its accuracy, or any practices or standards contained within it. Please confirm you wish to continue.